Clinical Trial

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2017-10-16; most recent amendment 2026-06-23.
Status change: Not Yet Recruiting → Recruiting 2018-05-18
Trial Details
NCT Number NCT03314974
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis +20 more
Enrollment 300 participants
Start Date 2018-03-30
Primary Completion 2027-06-10 (estimated)
Study Completion 2028-06-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-25